Adult stem cell developer Neuralstem Inc. said Monday the Food and Drug Administration approved the company's plan for a small, early-stage study of its treatment for spinal cord injury.
http://www.biosciencetechnology.com/news/2013/01/fda-clears-study-neuralstem-spinal-cord-therapy
http://www.biosciencetechnology.com/news/2013/01/fda-clears-study-neuralstem-spinal-cord-therapy
No comments:
Post a Comment